Target- |
MechanismCell replacements |
|
|
|
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
MechanismCell replacements |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
Clinical Research of Human Retinal Pigment Epithelial (HuRPE) Cell Injection on Atrophy of High Myopia Macular Area
To evaluate the safety and tolerability of human retinal pigment epithelial (HuRPE) cell injection subretinal transplantation for atrophy of high myopia macular area, and to explore the maximum tolerated dose (MTD).
Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis by Primary Retinal Pigment Epithelial Cells Transplantation
Early Phase I Study of the Safety and Preliminary Efficacy of Human primary Retinal Pigment Epithelial (HuRPE) Cells Subretinal Transplantation in Retinitis Pigmentosa (RP) and Leber Congenital Amaurosis (LCA) Patients
Clinical study of transplanting human retinal pigment epithelial cells for treatment of macular degeneration
100 Clinical Results associated with Jiangsu Aierkang Biomedical Technology Co., Ltd
0 Patents (Medical) associated with Jiangsu Aierkang Biomedical Technology Co., Ltd
100 Deals associated with Jiangsu Aierkang Biomedical Technology Co., Ltd
100 Translational Medicine associated with Jiangsu Aierkang Biomedical Technology Co., Ltd